['rheumatoid arthritis']
['placebo for adalimumab', 'adalimumab', 'placebo for upadacitinib', 'upadacitinib']

        Inclusion Criteria:

          -  Adult male or female, at least 18 years old.

          -  Diagnosis of RA for greater than or equal to 3 months.

          -  Subjects must have been on oral or parenteral methotrexate (MTX) therapy greater than
             or equal to 3 months and on a stable prescription of greater than or equal to 15 to 25
             mg/week (or greater than or equal to 10 mg/week in subjects intolerant of MTX at doses
             greater than or equal to 12.5 mg/week) for at least 4 weeks prior to the first dose of
             study drug. In addition all subjects should take a dietary supplement of folic acid or
             folinic acid throughout the study participation.

          -  Meets the following minimum disease activity criteria: greater than or equal to 6
             swollen joints (based on 66 joint counts) and greater than or equal to 6 tender joints
             (based on 68 joint counts) at Screening and Baseline Visits.

          -  At least one of the following at Screening: greater than or equal to 3 bone erosions
             on x-ray OR greater than or equal to 1 bone erosion and a positive rheumatoid factor
             OR greater than or equal to 1 bone erosion and a positive anti-cyclic citrullinated
             peptide autoantibodies.

          -  Subjects with prior exposure to only one biological disease-modifying anti-rheumatic
             drugs (bDMARD) (except adalimumab) may be enrolled (up to 20% of total study
             population) if they have documented evidence of intolerance to the bDMARD or limited
             exposure (less than 3 months), but required washout periods need to be satisfied.

          -  Except for MTX, subject must have discontinued all conventional synthetic
             disease-modifying anti-rheumatic drugs (csDMARDs).

        Exclusion Criteria:

          -  Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to
             tofacitinib, baricitinib, and filgotinib).

          -  Subjects who have been exposed to adalimumab or who are considered inadequate
             responders to bDMARD therapy as determined by the Investigator.

          -  History of inflammatory joint disease other than RA. History of secondary Sjogren's
             Syndrome is permitted.
      